Oral Semaglutide Reduces Heavy Drinking

A clinical trial led by researchers at the University of Colorado Anschutz found that oral semaglutide, a medication used for diabetes and weight loss, reduces heavy drinking in adults with Alcohol Use Disorder (AUD). The eight-week randomized, double-blind, placebo-controlled trial involving 50 adults showed fewer heavy drinking days, reduced alcohol consumption, lower cravings, and fewer alcohol-related problems. The study was published in The The American Journal of Psychiatry and funded in part by the United States — National Institute on Alcohol Abuse and Alcoholism. No new medications have been approved for AUD by the United States — Food and Drug Administration since 2006, highlighting the need for new treatments. Larger trials are planned.